Cancer treatment and research communications最新文献

{"title":"Distinct roles of WHO Score, CCI, and CFS in prognosis and treatment decisions for non-small cell lung cancer: A retrospective real-world study.","authors":"Ville Paappanen, Arja Jukkola, Tuula Klaavuniemi, Liisa Sailas, Jarkko Ahvonen, Hanne Kuitunen, Tuomas Selander, Maria Tengström, Miia Kärkkäinen, Outi Kuittinen, Satu Tiainen","doi":"10.1016/j.ctarc.2026.101235","DOIUrl":"https://doi.org/10.1016/j.ctarc.2026.101235","url":null,"abstract":"<p><strong>Background: </strong>Non-small cell lung cancer (NSCLC) is a major cause of cancer mortality, especially in older adults. While comprehensive patient assessment is crucial, the optimal combination of prognostic tools beyond the standard WHO Score is unclear. This study compared the prognostic value of WHO Score, Charlson Comorbidity Index (CCI), and Clinical Frailty Scale (CFS) in Finnish NSCLC patients.</p><p><strong>Materials and methods: </strong>This retrospective multicenter study included 395 NSCLC patients diagnosed in 2018 across five Finnish hospitals. Data on WHO Score, CCI, and CFS were collected (CFS data being available for approximately one-third-of the patients). Treatment allocation associations were analyzed using logistic regression. Survival outcomes (OS and DSS) were assessed using Kaplan-Meier and Cox regression models.</p><p><strong>Results: </strong>WHO Score was the primary predictor for OS and DSS in the main cohort but failed to predict survival in surgically treated patients. In the CFS subgroup (N = 117), CFS was a stronger predictor of treatment allocation than WHO Score (OR=2.57 for non-active treatment per point increase). While CFS was associated with survival, its independent prognostic value was not definitively established. CCI demonstrated limited additional prognostic value.</p><p><strong>Conclusions: </strong>WHO Score remains a robust prognostic indicator for survival in NSCLC. CFS shows significant potential in reflecting treatment decisions related to frailty, capturing risks not fully addressed by WHO Score. CCI offered minimal additive prognostic information. While WHO Score is fundamental, incorporating CFS enhances frail patient assessment, though its independent survival prediction value warrants further study.</p>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"47 ","pages":"101235"},"PeriodicalIF":2.4,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to Comprehensive clinical characteristics and outcomes of stage IV EGFR-mutant NSCLC based on PD-L1 expression, Cancer Treatment and Research Communications 46 (2026) 101109.","authors":"Jonathan W Lee, Xiao Jin, Stephanie Bogdan, Ayman Abou-Alfa, Josephine Chang, Michael Rafizadeh, Eric C Kang, Christine Garcia, Xi Kathy Zhou, Ashish Saxena","doi":"10.1016/j.ctarc.2026.101220","DOIUrl":"https://doi.org/10.1016/j.ctarc.2026.101220","url":null,"abstract":"","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":" ","pages":"101220"},"PeriodicalIF":2.4,"publicationDate":"2026-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147811332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A pilot study of quality of life domains before and after radiotherapy in patients with head and neck cancer.","authors":"Jacopo Lanzetti, Federica Ferrati, Matteo Bartolomeo, Armando Crupi, Umberto Gibello, Federico Mussano, Francesco Pera","doi":"10.1016/j.ctarc.2026.101232","DOIUrl":"https://doi.org/10.1016/j.ctarc.2026.101232","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of the study was to examine the worsening of QoL in patients with HNC before and after cancer therapy and to assess the extent that each factor has in its worsening.</p><p><strong>Methods: </strong>A prospective study was developed to analyze the QoL of patients with HNC before and after curative radiotherapy. The patients were interviewed to assess QoL within 15 days after initiation and at least 15 days after completion of radiotherapy. QoL assessment was performed by University of Washington Quality of Life Questionnaire version 4.1.</p><p><strong>Results: </strong>The questionnaire before and after radiotherapy was completed by 22 patients. \"Fear of recurrence\" was the main important domain pre- and post-radiotherapy. Regarding the global questions we noticed a lower percentage of patients who rated positively their QoL from before to after radiotherapy. It was possible to note that there were statistically significant differences for \"taste\" (p=0.018) and \"saliva\" (p<0.001). The comparison between Physical Function and Social-Emotional Function before and after radiotherapy showed that there was a statistically significant difference in QoL related to Physical Function, which worsens after radiotherapy.</p><p><strong>Conclusion: </strong>This pilot study showed that fear of recurrence is the most important domain for HNC patients undergoing radiation therapy, followed by saliva, taste and swallowing.</p>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"47 ","pages":"101232"},"PeriodicalIF":2.4,"publicationDate":"2026-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147811411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimodal liquid biopsy surveillance after pancreatectomy for pancreatic ductal adenocarcinoma: evidence and a confirmation‑gated, trial‑ready framework.","authors":"Lei Feng, Zhen You","doi":"10.1016/j.ctarc.2026.101226","DOIUrl":"https://doi.org/10.1016/j.ctarc.2026.101226","url":null,"abstract":"<p><p>Relapse after curative‑intent pancreatectomy for pancreatic ductal adenocarcinoma (PDAC) is common and may become clinically apparent only after a delay in conventional imaging and CA19‑9 monitoring. Liquid biopsy offers serial access to tumor‑derived signals, but post‑operative minimal residual disease (MRD) is often near the assay limit of detection, raising risks of false positives, over‑imaging, and premature treatment escalation outside trials. We performed a scoping review of clinical studies evaluating circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vehicles (EVs) in resected or curatively treated PDAC, focusing on recurrence prediction, lead time, and practical implementation. Across cohorts, tumor‑informed ctDNA and longitudinal CTC kinetics show consistent prognostic value and may precede radiographic recurrence by weeks to months, although sensitivity varies with tumor shedding patterns and assay design. EV markers and signatures provide complementary biology and may be informative in low‑shedding states, but reproducibility is limited by pre‑analytical and platform heterogeneity, necessitating conservative interpretation. We propose a pragmatic, confirmation‑gated trigger algorithm for \"liquid‑positive, imaging‑negative\" scenarios: borderline signals are considered indeterminate and prompt repeat sampling and/or orthogonal confirmation; imaging is expedited when ctDNA converts on serial draws or when concordant positivity is observed across two analytes (ctDNA/CTC/EV); and systemic therapy changes should be avoided outside prospective utility‑driven trials. Finally, we outline trial designs (ctDNA‑positive escalation, ctDNA‑negative de‑escalation, and strategy comparisons) incorporating survival, decision‑curve, and health‑economic endpoints to establish clinical utility.</p>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"47 ","pages":"101226"},"PeriodicalIF":2.4,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Downregulated extracellular matrix-associated CILP, MFAP4, and MMRN1 genes reveal links to immune infiltration and clinical outcomes in colorectal cancer: bioinformatics and experimental validation.","authors":"Erfan Golestannejad, Ashkan Kalantary-Charvadeh, Jamshid Karimi, Iraj Khodadadi","doi":"10.1016/j.ctarc.2026.101206","DOIUrl":"https://doi.org/10.1016/j.ctarc.2026.101206","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) is a leading cause of cancer mortality. The extracellular matrix (ECM) plays a critical role in tumor progression, and its associated genes may serve as prognostic biomarkers. This study investigated three ECM-related genes, CILP, MFAP4, and MMRN1, to evaluate their expression and clinical significance in CRC development.</p><p><strong>Methods: </strong>RNA-seq data from TCGA-COAD and microarray datasets (GSE23878, GSE89076) were analyzed to identify differentially expressed genes (DEGs). Bioinformatics analyses included functional enrichment, protein-protein interaction (PPI) network construction, and immune infiltration evaluation. Experimental validation was performed using RT-qPCR on 20 paired CRC and adjacent non-cancerous tissues. Associations between gene expression, clinicopathological features, and overall survival were assessed.</p><p><strong>Results: </strong>Both RNA-seq and microarray analyses revealed significant downregulation of CILP, MFAP4, and MMRN1 in CRC tissues compared to non-cancerous samples (p < 0.05). RT-qPCR confirmed lower expression levels in tumor tissues (p < 0.0001). TIMER database analysis for immune cell infiltration revealed positive correlations between target genes and tumor-infiltrating lymphocytes, particularly CD₈⁺ T cells and macrophages. Moreover, MFAP4 expression showed a significant association with lymph node status (p < 0.05), while both MFAP4 and MMRN1 were found to be correlated with smaller tumor size (p = 0.04). Survival analysis showed non-significant trends toward poorer prognosis in patients with lower gene expression.</p><p><strong>Conclusion: </strong>These findings demonstrated that CILP, MFAP4, and MMRN1 function as potential tumor suppressors and immunomodulators in CRC. Their significant downregulation in tumor tissues, along with associations with immune infiltration and clinical features, suggest a possible role in CRC pathogenesis and make them potential therapeutic targets.</p>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"47 ","pages":"101206"},"PeriodicalIF":2.4,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147855626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LINC02057 as a potential tumor marker for the aggressive renal cell carcinoma.","authors":"Meysam Moghbeli, Fatemeh Taghavinia, Alireza Golshan","doi":"10.1016/j.ctarc.2026.101225","DOIUrl":"https://doi.org/10.1016/j.ctarc.2026.101225","url":null,"abstract":"<p><strong>Background: </strong>Renal cell carcinoma (RCC) is a common urological malignancy with a favorable prognosis in early tumor stages. However, metastatic RCC exhibits low survival rates due to late-stage diagnoses. Thus, it is essential to investigate the molecular biology of RCC progression to develop effective tumor markers. Long non-coding RNAs (lncRNAs) play significant roles in regulating molecular mechanisms associated with RCC progression. This study evaluates LINC02057 expression levels in RCC patients to propose it as a potential tumor marker.</p><p><strong>Methods: </strong>Fresh tissues were collected from fifty RCC patients. LINC02057 expression levels were evaluated in tumor tissues versus normal margins via Real-time PCR to explore potential associations with RCC clinicopathological features.</p><p><strong>Results: </strong>There were significant higher levels of LINC02057 expressions in high-grade (III/IV) tumor compared with low-grade tumors (p = 0.017). Early stage (T1/2) tumors had significant lower levels of LINC02057 expressions compared with advanced stage (T3/4) tumors in female RCC patients (p = 0.042). There was positive correlation between expression level of LINC02057 and tumor size in patients older than 60 years old (p = 0.046).</p><p><strong>Conclusions: </strong>High-grade tumors with advanced stages have a high metastatic potential. Therefore, LINC02057 can be suggested as a potential marker for prediction of tumor aggressiveness among RCC patients.</p>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"47 ","pages":"101225"},"PeriodicalIF":2.4,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147811403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fluorescent chromophores in anticancer therapy: Mechanisms and advances.","authors":"Mani Rajasekar, Meenambigai Sivakumar","doi":"10.1016/j.ctarc.2026.101221","DOIUrl":"https://doi.org/10.1016/j.ctarc.2026.101221","url":null,"abstract":"<p><p>Fluorescent Chromophore compounds are characterized by their unique light-absorbing properties. They have emerged as promising candidates in anticancer research due to their ability to interact with cellular components through photodynamic, photothermal, and other therapeutic mechanisms. Recent advancements in synthetic chromophore compounds, such as Coumarin, Fluorescein, Quinoline, and Rhodamine have demonstrated significant anticancer activity by inducing apoptosis, inhibiting cell proliferation, and disrupting tumor vasculature. The integration of chromophores with nanotechnology and targeted drug delivery systems has enhanced their therapeutic efficacy and selectivity, minimizing side effects. Moreover, their role in photoactivation has opened avenues for non-invasive cancer treatments. Despite these advances, challenges such as drug resistance, limited bioavailability, and potential toxicity need to be addressed. This review summarizes recent developments in fluorescent chromophore-based anticancer therapies, highlighting their mechanisms and potential in combination strategies, while addressing future directions for overcoming current limitations in clinical applications.</p>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"47 ","pages":"101221"},"PeriodicalIF":2.4,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147811347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Casein-based nanocarriers for myricetin delivery: Enhancement of apoptosis and inhibition of angiogenesis in gastric adenocarcinoma cells.","authors":"Saemeh Sadeghieh, Niloufar Khatibzade-Nasari, Hilda Besharat, Ehsan Oskoueian, Ehsan Karimi","doi":"10.1016/j.ctarc.2026.101224","DOIUrl":"https://doi.org/10.1016/j.ctarc.2026.101224","url":null,"abstract":"<p><p>The challenges of conventional chemotherapy's side effects highlight the need for new treatments. Phytochemicals like myricetin show promise in cancer therapy, but their bioavailability is limited due to poor solubility and rapid clearance, requiring nanocarriers for improved delivery. This study focused on synthesizing and characterizing myricetin-encapsulated casein nanoparticles (M-CNPs) and evaluating their effects on angiogenesis and pro-apoptotic activities in human gastric adenocarcinoma (AGS) cells. M-CNPs were characterized using Dynamic Light Scattering (DLS), Scanning Electron Microscopy (SEM), and Fourier Transform Infrared Spectroscopy (FTIR). Cytotoxicity was assessed via MTT assay, and cell cycle and apoptosis studies were conducted using flow cytometry and AO/PI staining. Key gene expression, including Caspase 3, Caspase 9, and MMP-2, was analyzed by real-time PCR. The anti-angiogenic effects of M-CNPs were evaluated using the chick chorioallantoic membrane (CAM) assay. The results showed that M-CNPs are spherical, averaging 75.38 nm in size with a polydispersity index of 0.31, indicating uniformity in particle distribution. MTT analysis revealed a dose-dependent reduction in AGS cell viability, while AO/PI staining and flow cytometry confirmed that M-CNPs induce apoptosis and cell cycle arrest. Gene expression analysis indicated upregulation of Caspase 3 (p > 0.05) and downregulation of MMP-2 (p ≤ 0.05). The CAM assay demonstrated significant anti-angiogenic effects and downregulated VEGFR expression (p ≤ 0.05). These findings suggest that M-CNPs could be an effective cancer treatment by enhancing myricetin bioavailability and targeting multiple pathways.</p>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"47 ","pages":"101224"},"PeriodicalIF":2.4,"publicationDate":"2026-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147811328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to 'Clinical characteristics and survival outcomes of young women with luminal HER2-low and HER2-ultralow breast cancer' [Cancer Research and Treatment Communications 46 (2026) 101112].","authors":"Jesus Edgardo Hernandez-Hernandez, César Octavio Lara-Torres, Alejandro Aranda-Gutiérrez, Víctor A Domínguez-Porras, Bryan Moreno-Moran, Héctor Díaz-Pérez, Gabriela Sofía Gómez-Macías, Paula Cabrera-Galeana, Cynthia Villarreal-Garza, Alejandro Mohar","doi":"10.1016/j.ctarc.2026.101149","DOIUrl":"https://doi.org/10.1016/j.ctarc.2026.101149","url":null,"abstract":"","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":" ","pages":"101149"},"PeriodicalIF":2.4,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147430757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determinants of delayed postoperative radiation therapy in breast cancer patients undergoing neoadjuvant chemotherapy: A subanalysis of the AMAZONA III prospective cohort","authors":"Júlio César Prestes ,&nbsp;Gustavo Viani ,&nbsp;Andre Guimaraes Gouveia ,&nbsp;Maurício Fraga da Silva ,&nbsp;Fabio Ynoe. Moraes ,&nbsp;Daniela Dornelles Rosa ,&nbsp;Carlos Henrique Escosteguy Barrios ,&nbsp;Gustavo Werutsky ,&nbsp;Jose Bines ,&nbsp;Eduardo Henrique Cronemberger Costa e Silva ,&nbsp;Geraldo Silva Queiroz ,&nbsp;Fabiana Baroni Makdissi ,&nbsp;Vladmir Cordeiro de Lima ,&nbsp;Ruffo Freitas-Junior ,&nbsp;José d'Oliveira Couto Filho ,&nbsp;Karla Emerenciano ,&nbsp;Heloisa Magda Resende ,&nbsp;Susanne Crocamo ,&nbsp;Tomas Reinert ,&nbsp;Brigitte Van Eyll ,&nbsp;Gustavo Nader Marta","doi":"10.1016/j.ctarc.2026.101119","DOIUrl":"10.1016/j.ctarc.2026.101119","url":null,"abstract":"<div><h3>Background</h3><div>Delays in starting postoperative radiation therapy (PORT) in breast cancer patients may be associated with poorer clinical outcomes. This analysis aimed to identify factors contributing to delayed PORT in patients with breast cancer who underwent neoadjuvant chemotherapy followed by surgery and PORT in a Brazilian cohort.</div></div><div><h3>Methods</h3><div>Participants were categorized based on the interval from surgery to the initiation of PORT into two groups: ≤ 8 weeks and &gt; 8 weeks. Socioeconomic and clinicopathological factors were analyzed for associations with delayed PORT. Univariable and multivariable regressions were performed.</div></div><div><h3>Results</h3><div>Factors significantly associated with delayed PORT included low educational level (RR: 1.50; 95 % CI: 1.05–2.14; <em>p</em> = 0.0276), public health insurance (RR: 3.29; 95 % CI: 1.76–6.12; <em>p</em> = 0.0002) and having a Luminal A or Luminal B-HER2-negative subtype (RR: 1.92; 95 % CI: 1.14–3.23; <em>p</em> = 0.0153) compared to the Triple Negative subtype. The absence of adjuvant endocrine therapy was associated with a lower risk of delayed PORT (RR: 0.67; 95 % CI: 0.46–0.99; <em>p</em> = 0.0338). In the multivariate analysis, public health insurance remained the sole independent predictor of delayed PORT (RR: 2.98; 95 % CI: 1.60–5.55; <em>p</em> = 0.0006).</div></div><div><h3>Conclusion</h3><div>In this cohort, reliance on public health insurance emerged as the primary independent predictor of delayed initiation of PORT in breast cancer patients who received neoadjuvant chemotherapy. Lower educational levels and household income also contributed to delays, highlighting disparities within the healthcare system. Addressing these barriers is essential for improving timely access to PORT and potentially enhancing clinical outcomes in this population.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"47 ","pages":"Article 101119"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146172398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}